Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sue Richter"'
Publikováno v:
Journal of Clinical Oncology. 34:78-78
78 Background: High-grade neuroendocrine tumours (NETs) are believed to have activity to certain alkylating agents, although data are scant. These regimens include streptozotocin (STZ) (used in combination with doxorubicin or 5-fluorouracil) and daca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b147ba7dce5cc741193d55c5cef2aa56
https://doi.org/10.1200/jco.2016.34.7_suppl.78
https://doi.org/10.1200/jco.2016.34.7_suppl.78
Autor:
Sue Richter, Michael Milosevic, Neil Fleshner, Nafisha Lalani, Robert G. Bristow, Alexandre R. Zlotta, Srikala S. Sridhar, Peter Chung, Michael Jewett
Publikováno v:
Journal of Clinical Oncology. 32:320-320
320 Background: For select muscle invasive bladder cancer (MIBC) patients, a multimodal approach using transurethral resection of the bladder tumor (TURBT) followed by concurrent cisplatin and external beam radiotherapy (EBRT) provides a curative bla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49c12b1268db6cdf80c66152603e2c92
https://doi.org/10.1200/jco.2014.32.4_suppl.320
https://doi.org/10.1200/jco.2014.32.4_suppl.320
Autor:
Srikala S. Sridhar, Christine Massey, David Wiljer, Pamela Catton, Ashraf Almatar, Jackie Bender, Laura Legere, Majula Maganti, Nafisha Lalani, Nour Alkazaz, Michael Jewett, Sue Richter
Publikováno v:
Journal of Clinical Oncology. 31:337-337
337 Background: Genitourinary (GU) cancer survivors comprise nearly 25% of cancer survivors and >50% of all male survivors. To further improve care of this patient population, we need to better understand physician specialist perceptions of survivors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9f926bac9f438a2d93d0a263deb8fa4
https://doi.org/10.1200/jco.2013.31.6_suppl.337
https://doi.org/10.1200/jco.2013.31.6_suppl.337
Publikováno v:
Journal of Clinical Oncology. 30:e15020-e15020
e15020 Background: Gender differences for disease course and survival in various cancers exist. Gender disparity for both stage at diagnosis and overall survival (OS) has been observed in urothelial cancer (UC). We report a single institution analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce2d267ad978b50490e62c3463a3cd07
https://doi.org/10.1200/jco.2012.30.15_suppl.e15020
https://doi.org/10.1200/jco.2012.30.15_suppl.e15020
Autor:
Ben Tran, Eric Chen, Albiruni Ryan Abdul Razak, Kristina Battista, Elaine McWhirter, S. Percy Ivy, Anne Laughlin, Lee-Anne Stayner, Hal W. Hirte, Sebastien J. Hotte, Lisa Wang, Philippe L. Bedard, Lillian L. Siu, Anastasios Stathis, Sue Richter, Malcolm J. Moore, Amit M. Oza
Publikováno v:
Journal of Clinical Oncology. 30:3082-3082
3082 Background: RO4929097 (RO) is an oral inhibitor of γ-secretase that disrupts Notch signaling. Gemcitabine (GEM) is active against many solid tumors with a favorable toxicity profile suited to combination. The primary objective of this trial is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3497d0dc1d8f662b7b97fdf0ceb0195
https://doi.org/10.1200/jco.2012.30.15_suppl.3082
https://doi.org/10.1200/jco.2012.30.15_suppl.3082
Publikováno v:
Journal of Clinical Oncology. 30:1555-1555
1555 Background: Genetic testing for BRCA1 and BRCA2 is an instrumental tool in clinical decision-making. Variants of uncertain significance (VUS) can occur in up to 25% of individuals and pose clinical challenges. We compared i) result recall ii) ri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66ae05093224991319b5ac0609d04c38
https://doi.org/10.1200/jco.2012.30.15_suppl.1555
https://doi.org/10.1200/jco.2012.30.15_suppl.1555